Improving Patient Survival in High Mortality Cancers

Sapience Therapeutics is focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. Sapience identifies promising targets through a deep understanding of the transcriptional regulation of oncogenic or immune-modulatory proteins.  Our targets are non-traditional in drug discovery as they do not demonstrate enzymatic activities or act as ligand-binding receptors. Sapience has multiple approaches to generate initial hits, which are then optimized based on decades of experience working with peptide and protein therapeutics.  ST101 went from concept to clinical candidate in less than 9 months.

Several key partnerships with top academic research institutions support Sapience’s discovery and development efforts.

Discovery Partnership with University of Bath

Sapience partnered with the University of Bath to discover new anti-cancer peptides that disrupt specific intracellular protein-protein interactions.  Together, we will employ a protein fragment complementation approach and include additional competitive and negative design components to discover highly specific peptides that disrupt pathophysiologic protein-protein interactions.  We will operate the discovery platform at the University of Bath and in-house at Sapience Therapeutics.

Development Partnership with Columbia University

Sapience is the exclusive licensee of certain intellectual property owned by Columbia University. The license includes a proof-of-concept ATF5-mimetic molecule that has more than a decade of research supporting its mechanistic approach to treating cancer. Through our proprietary methodology, we modified the initial concept to a development lead, ST101, which is being developed for the treatment of AML and solid tumors, incluing GBM.

Science Backed by Strong Leadership

Our world-class team of executives and scientists are helping us pave the way to providing therapeutics for significant unmet medical needs.